# Andrew Chadeayne

> Andrew Chadeayne is the founder and CEO of CaaMTech, an Issaquah, Washington psychedelic pharmaceutical company building safer, patentable psychedelic-inspired medicines. A chemist (PhD, Cornell) and patent attorney (JD, George Washington) who began his career proving sugar is addictive through opioid pathways, he has filed more than 100 patent applications mapping the chemistry of psilocybin, tryptamines and other psychedelics. His strategy is to expand 'the universe of available compounds' rather than bet on a single molecule, giving researchers a toolbox of characterized psychedelics for mental health treatment.

- **Role:** Founder and Chief Executive Officer at CaaMTech
- **Organizations:** CaaMTech, Ebbu, SwimSpray
- **Nationality:** American
- **Education:** B.A., Neuropsychology and Chemistry, Princeton University, Ph.D., Chemistry, Cornell University, J.D., Patent Law, The George Washington University Law School
- **Known for:** Founded CaaMTech and raised $22M Series A funding, Filed more than 100 patent applications mapping psychedelic chemistry, Co-author of foundational research showing sugar can be addictive via opioid pathways

## Career timeline

- **2002** — Co-authored study in Obesity Research showing intermittent excessive sugar intake causes endogenous opioid dependence.
- **2006** — Earned Ph.D. in Chemistry from Cornell University.
- **2011** — Earned J.D. in patent law; awarded the American Bar Association's Award for Excellence in Intellectual Property.
- **2013** — Founded SwimSpray, a water-soluble vitamin C spray to remove chlorine from swimmers' skin and hair.
- **2017** — Joined cannabis technology firm Ebbu as Chief Innovations Officer, building a worldwide patent portfolio.
- **2018** — Ebbu's assets acquired by Canopy Growth Corporation in a deal valued at $330M+.
- **2019** — Founded CaaMTech in Issaquah, Washington.
- **2021** — Closed $22M Series A; partnered with University of Wyoming to study psychedelics for addiction.

## Achievements

- Founded CaaMTech and raised $22M Series A funding
- Filed more than 100 patent applications mapping psychedelic chemistry
- Co-author of foundational research showing sugar can be addictive via opioid pathways
- American Bar Association Award for Excellence in Intellectual Property (2011)
- Built the worldwide patent portfolio at Ebbu, acquired by Canopy Growth for $330M+
- Invented and commercialized SwimSpray

## Latest updates

- **2021-11** — CaaMTech partnered with the University of Wyoming to study psychedelics as treatments for addiction.
- **2021-09** — Closed $22M Series A funding round.

## Links

- Website: https://caam.tech
- LinkedIn: http://www.linkedin.com/in/andrew-chadeayne-989b751
- Twitter/X: https://twitter.com/CaaMTechInc
- Facebook: https://www.facebook.com/CaaMTechInc/

---

Profile page: https://yespress.io/andrew-chadeayne
Published by YesPress — https://yespress.io
Last updated: 2026-06-14